While Praxis moves forward, Neurocrine drops its essential tremor drug
While Neurocrine Biosciences continues to grow the sales of its tardive dyskinesia drug for patients who experience uncommon side effects from mental health drugs, it hit a snag in its development of an essential tremor drug.
In a Phase II study with 30 patients, the candidate, a T-type calcium channel blocker dubbed NBI-827104, did not meet its endpoints, and Neurocrine doesn’t plan to study the drug further for essential tremor, CMO Eiry Roberts said during Neurocrine’s Q2 investor call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.